Functional Significance of the Novel H-RAS Gene Mutation M72I in a Patient with Medullary Thyroid Cancer

Abstract

Medullary thyroid cancer (MTC) accounts for around 5–10% of all thyroid cancers. Though usually sporadic, 1 in 4 cases are of genetic origin, with germinal mutations in the RET proto-oncogene in familial forms and somatic mutations both in RET and in the RAS family genes in sporadic ones.

This study aimed to characterize a rare H-RAS sequence variant -M72I- in a patient with sporadic MTC, focusing on its functional significance.

Mutation analysis was performed for the RET, N-RAS, K-RAS and H-RAS genes by direct sequencing. Western blot analysis was done on 4 thyroid tissues from 1 patient carrying the M72I mutation in H-RAS, 1 with the Q61R mutation in H-RAS, 1 with no RET, H-RAS, K-RAS or N-RAS gene mutations, and 1 normal thyroid, using different antibodies against Erk1/2, phospho-Erk1/2 (Thr202/Tyr204), Akt and phospho-Akt (Ser473). Large-scale molecular dynamics simulations were completed for H-RAS wt and H-RAS M72I.

Western blot analysis demonstrated that both MAPK and PI3K/Akt pathways were activated in the MTC patient carrying the M72I variant. In silico results showed conformational changes in H-RAS that could influence its activation by Sos and phosphate binding. Results of molecular dynamics were consistent with Western blot experiments.

The M72I mutation may contribute effectively to proliferation and survival signaling throughout the MAPK and PI3K/Akt pathways. This work underscores the importance of studying genetic alterations that may lead to carcinogenesis.

Key words

H-RAS - MTC - thyroid cancer - M72I - case report

^* S.B. and R.P. should be regarded as co-First Authors and co-Corresponding Authors.

• References

• 1 Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985; 42: 581-588
• 2 Leboulleux S, Baudin E, Travagli JP et al. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004; 61: 299-310
• 3 Horie H, Yokogoshi Y, Tsuyuguchi M et al. Point mutations of ras and Gsα subunit genes in thyroid tumors. Jpn J Cancer Res 1995; 86: 737-742
• 4 Xing M, Vasko V, Tallini G et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 2004; 89: 1365-1368
• 5 Ciampi R, Mian C, Fugazzola L et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 2013; 23: 50-57
• 6 Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 7^th edition. Wiley-Blackwell; 2009: 58-62
• 7 Mariniello B, Rosato A, Zuccolotto G et al. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocr Relat Cancer 2012; 19: 527-539
• 8 Berman HM, Westbrook J, Feng Z et al. The Protein Data Bank. Nucleic Acids Research 2000; 235-242
• 9 Molecular Operating Environment (MOE) n.d. http://www.chemcomp.com
• 10 Cristiani A, Brisotto N, Cedrati FC et al. ClickMD: An intuitive web-oriented molecular dynamics platform. Future Medicinal Chemistry 2011; 923-931
• 11 Hornak V, Abel R, Okur A et al. Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins: Structure, Function, and Bioinformatics 2006; 65: 712-725
• 12 Phillips JC, Braun R, Wang W et al. Scalable molecular dynamics with NAMD. Journal of Computational Chemistry 2005; 26: 1781-1802
• 13 Harvey MJ, Giupponi G, De Fabritiis G. ACEMD: Accelerating biomolecular dynamics in the microsecond time scale. Journal of Chemical Theory and Computation 2009; 5: 1632-1639
• 14 Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. Journal of Molecular Graphics 1996; 14: 33-38
• 15 RMSD Trajectory Tool n.d http://physiology.med.cornell.edu/faculty/hweinstein/vmdplugins/rmsdtt/
• 16 Boriack-Sjodin PA, Margarit SM, Bar-Sagi D et al. The structural basis of the activation of Ras by Sos. Nature 1998; 394: 337-343
• 17 Mian C, Pennelli G, Barollo S et al. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol 2011; 164: 971-976
• 18 Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 19; 366: 207-215